Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 85

Using amantadine to help stroke recovery

Official title: Promoting Recovery After STroke With Amantadine

Run by University of Pennsylvania · NCT05140148 · Data updated 2026-11-12

This study tests if the medication amantadine can help people recover better after having a stroke.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 85 Years
SexAll
Enrollment60 (estimated)
SponsorUniversity of Pennsylvania
Academic / other
Locations1 site (Philadelphia, Pennsylvania)
StatusRecruiting
StartedFebruary 1, 2022
Main results expectedDecember 31, 2027
Study endsJune 30, 2028
Registry record updatedMarch 30, 2026
Trial IDNCT05140148 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 to 85 who have experienced an ischemic or hemorrhagic stroke and meet specific neurological assessment criteria.

Probably not a fit

Patients with significant expressive or receptive aphasia, or those with primary subarachnoid hemorrhage, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of amantadine in promoting recovery in patients who have experienced ischemic or hemorrhagic strokes. Participants will be randomly assigned to receive either amantadine or a placebo for one month, with a total enrollment period of three months. Throughout the trial, patients will undergo assessments and complete questionnaires to evaluate their recovery progress. The study aims to provide insights into the potential benefits of amantadine for stroke rehabilitation.

Why it matters

Potential benefit: If successful, this study could enhance recovery outcomes for stroke patients, potentially improving their quality of life.

How similar studies have gone: Previous studies have explored the use of amantadine for stroke recovery, showing promising results, but this specific approach is still being evaluated.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. 18 to 85 years old, male and female
2. Modified Rankin Score (mRS)\<=2 prior to stroke
3. Ischemic or hemorrhagic stroke as diagnosed by vascular neurologist or as proven on magnetic resonance imaging (MRI) or non-contrast head computed tomography NCHCT)
4. 24 hours to 3 weeks after stroke onset or time last known well prior to detection of symptoms
5. National Institute of Health Stroke Scale (NIHSS)\>=3 and NIHSS\<=15
6. Creatinine Clearance of greater than or equal to 60 mL/min using the Cockroft- Gault equation.
7. Have passed a swallow evaluation prior to drug administration
8. The patient is an acute rehabilitation candidate or candidate for the Homeward Stroke Program
9. Able to participate in administered tests

Exclusion Criteria:

1. Any degree of receptive aphasia
2. Moderate or severe expressive aphasia
3. Currently pregnant or plans to get pregnant
4. Currently breastfeeding
5. Any patient admitted with primary SubarachnoidH emorrhage (SAH )on either non-contrast head CT or MRI brain
6. Diagnosis of dementia or mild cognitive impairment prior to index stroke
7. Prior limb amputation
8. Currently prescribed or taking a primary anticholinergic medication
9. Currently enrolled in any other investigational pharmacologic or procedural clinical trial
10. Malignancy with active treatment
11. History of prior stroke with residual impairment
12. Current or prior neuroleptic use
13. History of suicidality or psychosis (The Columbia Suicide Severity Ratings Scale (C-SSRS) will be administered at the screening visit to assess depression and suicidal thoughts for subject eligibility. Any subjects who indicate severe depression or suicidal thoughts and/or attempts within the last year will not be eligible)
14. Prior history of seizures
15. Prior treatment with amantadine
16. Parkinson's disease
17. Amantadine allergy
18. Elevated liver function tests (aspartate aminotransferase and alanine aminotransferase above the upper limit of normal) -

Where it's running

  • The Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.